Pfizer signs Enodia Therapeutics research and licensing agreement worth more than $500 million for Sec61 protein degradation
Pfizer has entered a research and licensing collaboration with Enodia Therapeutics worth potentially more than $500 million to develop small-molecule therapies targeting protein synthesis through Sec61 inhibition.
Enodia will discover and optimise small-molecule Sec61 inhibitors against multiple collaboration targets using its targeted protein degradation platform, while Pfizer will assume responsibility for subsequent clinical development, manufacturing, regulatory activities and commercialisation.
The agreement includes an upfront payment, research funding, potential development and sales milestones and tiered royalties, positioning the partnership as a substantial investment in a differentiated protein-targeting approach.
Field | Content |
Article Type | Deals |
Companies | Pfizer; Enodia Therapeutics |
Deal Type | Research collaboration and licensing agreement |
Potential Deal Value | More than $500 million |
Upfront Payment | Included; individual amount not disclosed |
Research Funding | Included; amount not disclosed |
Milestone Payments | Potential research, development and sales milestones |
Royalties | Tiered royalties on future sales |
Technology/Modality | Small-molecule Sec61 inhibition and targeted protein degradation |
Molecular Target | Sec61 protein translocation complex |
Collaboration Scope | Discovery and optimisation of small-molecule Sec61 inhibitors against multiple collaboration targets |
Enodia Responsibilities | Research-stage discovery and optimisation of candidate inhibitors |
Pfizer Responsibilities | Clinical development, manufacturing, regulatory activities and commercialisation following the research phase |
Development Stage | Research and discovery |
Therapy Areas | Not specified in the supplied announcement summary |
Geography | Global collaboration |
What Happened | Pfizer and Enodia Therapeutics signed a research and licensing agreement potentially worth more than $500 million focused on small-molecule Sec61 inhibitors. |
Why It Matters | The collaboration provides external validation and substantial potential funding for Enodia's protein-targeting technology while expanding Pfizer's access to differentiated drug discovery approaches. |
Supporting Context | Sec61 is involved in protein translocation during synthesis and represents a distinct intervention point for developing therapies against selected protein targets. |
Strategic Rationale | Pfizer gains access to Enodia's specialised discovery platform while Enodia benefits from Pfizer's development and commercialisation capabilities. |
Potential Impact | Successful research could generate new therapeutic candidates targeting proteins through inhibition of their synthesis and processing. |
Key Takeaway | Pfizer has committed to a research and licensing partnership with Enodia carrying potential payments exceeding $500 million. |
What to Watch | Disclosure of collaboration targets, research milestones, candidate nominations, development progression and milestone payments. |
Primary Source | Enodia Therapeutics |
Relevant Date | 13 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Kommentare